文献速递泌尿生殖与妇科肿瘤放疗

239例宫颈癌患者基于三维MRI近距离放疗的单中心经验:剂量能否克服反应不佳

Single-Institution Experience in 3D MRI-Based Brachytherapy for Cervical Cancer for 239 Women: Can Dose Overcome Poor Response?
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-12-31

该单中心回顾性研究评估239例宫颈癌患者2007至2018年接受高剂量率近距离放疗的剂量学与结局,中位随访28.6个月,5年局部控制率为90.8%。多变量分析显示腺癌(HR 4.141)和HRCTV>40 cm3(HR 3.640)与更差局部控制相关,HRCTV EQD2 D90>85 Gy未在任何亚组中显著改善结局。

要点

  • 全队列5年局部控制率为90.8%,中位HRCTV D90为83.9 Gy。
  • 腺癌(HR 4.141)和HRCTV>40 cm3(HR 3.640)是多变量分析中局部控制的独立不良预后因素。
  • HRCTV EQD2 D90>85 Gy未在任何亚组中显著改善结局。

核心结论

  • 基于磁共振成像的计划在全队列中局部控制优秀。
  • 对外照射反应不佳(HRCTV较大)和腺癌组织学预测更差局部控制,尽管与更高近距离放疗处方相关。
  • 具有这些风险因素的患者面临更高的盆腔外进展率和更差的总生存。

研究设计与样本

  • 单中心回顾性研究,评估2007至2018年接受高剂量率近距离放疗的239例宫颈癌患者的剂量学与结局。
  • 采用Kaplan-Meier法及单变量和多变量Cox回归分析评估肿瘤参数对局部控制的意义,采用线性回归模型确定相关性。

主要发现

  • 中位随访28.6个月,中位处方剂量为27.5 Gy分5次,中位HRCTV D90为83.9 Gy(范围81.9-85.7 Gy),中位HRCTV体积为31 cm3(范围14.9-121.9 cm3),中位治疗时间为51天(范围36-83天)。
  • 全队列5年局部控制率为90.8%。
  • 多变量分析中,腺癌(HR 4.141;95%CI 1.498-11.444;P=.006)和HRCTV>40 cm3(HR 3.640;95%CI 1.316-10.069;P=.013)与更差局部控制相关。
  • HRCTV>40 cm3组2年无进展生存率为66.2%,≤40 cm3组为84.1%(P<.001)。
  • HRCTV≤40 cm3组2年总生存率为90.4%,>40 cm3组为68.5%(P<.001)。

关键数值与推荐

  • 近期欧洲妇科放射治疗学会-欧洲放射肿瘤学会(Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology)指南推荐宫颈癌高危临床靶区(HRCTV)90%体积剂量(D90)至少为85 Gy,对放疗反应不佳者给予更高剂量。
  • 本研究中HRCTV EQD2 D90>85 Gy未在任何亚组中显著改善结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology guidelines recommend that the dose to 90% (D90) of the high-risk clinical target volume (HRCTV) in cervical cancer be at least 85 Gy, with higher doses for poor response to radiation therapy. METHODS AND MATERIALS: A retrospective review of brachytherapy delivered at a single institution was evaluated for dosimetry and outcomes. Significance of tumor parameters on local control was evaluated with Kaplan-Meier and univariable and multivariable Cox regression analysis. Correlations were determined with a linear regression model. RESULTS: A total of 239 women underwent high-dose-rate brachytherapy for cervical cancer between 2007 and 2018 with evaluable dosimetry. Median follow-up was 28.6 months. The median prescribed dose was 27.5 Gy in 5 fractions, with a median HRCTV D90 of 83.9 Gy (range, 81.9-85.7 Gy), HRCTV volume of 31 cm3 (range, 14.9-121.9 cm3), and treatment time of 51 days (range, 36-83 days). Local control for the entire cohort at 5 years was 90.8%. Local control was worse with adenocarcinomas, HRCTV >40 cm3 at brachytherapy, requirement for a higher brachytherapy dose, and treatment >51 days. On multivariable analysis, local control was worse with adenocarcinoma (hazard ratio, 4.141; 95% confidence interval, 1.498-11.444; P = .006) and HRCTV >40 cm3 (hazard ratio, 3.640; 95% confidence interval, 1.316-10.069; P = .013). HRCTV EQD2 D90 > 85 Gy did not statistically improve outcomes for any subset. The 2-year progression-free survival for HRCTV >40 cm3 was 66.2% versus 84.1% if ≤40 cm3 (P < .001). Overall survival was predicted by HRCTV and overall treatment time in multivariable analysis. For women with HRCTV ≤40 cm3, overall survival at 2 years was 90.4% versus 68.5% if >40 cm3 (P < .001). CONCLUSION: Local control was excellent with magnetic resonance imaging-based planning in the entire cohort of patients. A poor response to external beam radiation (larger HRCTV) and adenocarcinoma histology predicted for worse local control despite association with higher brachytherapy prescription. Women with these risk factors face higher rates of extrapelvic progression and poorer overall survival.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Horne ZD, Karukonda P, Kalash R, et al. Single-Institution Experience in 3D MRI-Based Brachytherapy for Cervical Cancer for 239 Women: Can Dose Overcome Poor Response? Int J Radiat Oncol Biol Phys. 2018. PMID: 30605752. doi:10.1016/j.ijrobp.2018.12.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。